Answers are grounded in this paper and cite their sources.
Objective The aim of this study was to explore whether inflammation related to thalassemia has a relation with serum level of calprotectin as an inflammatory marker in children. Materials and methods In this case–control study, 40 patients with β-thalassemia major (BTM) receiving regular blood transfusion aged 4–15 years and a group of 20 healthy children were enrolled. Serum concentration of calprotectin was measured and correlated with the duration of the disease and the frequency of blood transfusion. Results There was a significant difference between thalassemic patients and controls as regards the mean level of serum calprotectin (P<0.001). Calprotectin level was higher in splenectomized thalassemic patients than in nonsplenectomized ones (P=0.01). Moreover, the level of calprotectin was higher in thalssemic patients with a disease duration of more than 6 years than in those with a disease duration of less than 6 years (P<0.001), and calprotectin levels were higher in thalassemic patients with a frequency of blood transfusion of less than 3 weeks than in patients with a frequency of blood transfusion of more than 3 weeks (P=0.01). There was a significant positive correlation between calprotectin and duration of the disease (r=0.5, P=0.002), and a nonsignificant negative correlation between calprotectin and the frequency of blood transfusion (r=−0.2, P=0.2). Conclusion The higher levels of calprotectin among patients with BTM indicated the possible inflammatory role of this marker in BTM. As there is a significant positive association between calprotectin and duration of thalassemia, calprotectin can be used as a marker to detect inflammation and subsequent complication early in the disease.
No takes yet. Share an insight, caveat, or question.
Kassas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: